Feds probe ISTA promotions

Share this article:
ISTA Pharmaceuticals issued a statement reporting a subpoena received from the US Attorney's Office in Buffalo, “requesting the production of documents regarding promotional, educational and other activities relating to Xibrom (bromfenac sodium ophthalmic solution) 0.09%.”  

Xibrom is an ophthalmic solution indicated for the treatment of inflammation and ocular pain following cateract surgery.  Representatives of ISTA Pharmaceuticals were not immediately available for comment.

ISTA Pharmaceuticals previously reported clinical trial data showing “no statistically significant difference” between Xibrom and a new product, Xibrom QD.  Xibrom QD, to be taken once-per-day, would potentially replace Xibrom, taken twice-per-day.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.